Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus

Table 3

Logistic regression model predicting final HbA1C levels in 118 patients with hepatitis C and diabetes mellitus ().

Covariate (1)	Reference variable (0)	Estimate	Chi square	value
Age	—	-0.080	4.490	0.034
Gender	Female	0.015	0.000	0.975
Race	Black	0.413	0.560	0.453
Viral load	—	-4.9-8	0.460	0.497
Genotype 1	Non-1	-0.104	0.080	0.772
Moderate/severe chronic hepatitis	Minimal/mild chronic hepatitis	0.474	0.960	0.326
Baseline serum ALT level	—	-0.026	7.090	0.008
Baseline serum AST level	—	0.029	7.190	0.007
Baseline BMI	—	-0.064	2.280	0.131
Pretreatment HbA1C	—	0.209	1.730	0.189
Severe fibrosis or cirrhosis	No, mild, or significant fibrosis	0.066	0.020	0.889
Treatment with DAAs	No treatment	1.609	25.12	<0.0001

. ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; DAAs: direct acting antiviral agents for HCV; HbA1C: hemoglobin A1C level (%); HCV: hepatitis C virus; : probability.